Nurix Therapeutics, Inc. NRIX Internal research and development expenses — R&D

Similar metrics at other companies

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

INVAInternal Expenses — Research And Development Expense

$2.64M+95.9%

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

Questions, answered.

What is Nurix Therapeutics, Inc.'s internal research and development expenses — R&D?

Nurix Therapeutics, Inc. (NRIX) reported internal research and development expenses — R&D of $57.07M in Q4 2025.

How has Nurix Therapeutics, Inc.'s internal research and development expenses — R&D changed year-over-year?

Nurix Therapeutics, Inc.'s internal research and development expenses — R&D increased by 12.2% year-over-year, from $50.88M to $57.07M.

What does internal research and development expenses — R&D mean?

This metric represents the total costs incurred by the company for internal research and development activities focused on the discovery and advancement of novel therapeutic candidates. It captures the investment in proprietary drug development programs, including preclinical studies and clinical trials, essential for building the company's pipeline. Monitoring this expenditure provides insight into the company's commitment to innovation and its long-term strategy for commercializing new medical treatments.